Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-24 @ 2:43 PM
Ignite Modification Date:
2025-12-24 @ 2:43 PM
NCT ID:
NCT00308659
Brief Summary:
Main hypothesis: microbiological diagnossis off severe community acquired pneumonia can be performed by non invasive or semi invasive microbiological tools, semi invasive tools including protected distal bronchial samplings by the mean of Fiber optic bronchoscopy (FOB). A microbiological diagnosis could improve antibiotic therapy efficacy and improve patient's outcome.
These Two strategies have never been prospectivally evauated.
* Aim of the study: To evaluate 2 diagnostic strategies: non invasive or semi invasive including protected distal bronchial samplings by the mean of Fiber optic bronchoscopy (FOB)for the care of patients admitted in intensive care for severe community acquired pneumonia and receiving an empirical antibiotic therapy as recommanded by 2001 American thoracic guidelines
* Type of study randomized multicentric controlled open study
Detailed Description:
ď‚·Type of study randomized multicentric controlled open study
Number of patients: 200 patients (100 patients in each group)admitted in ICU for SCAP
* Number of center : 5
* Clinical strategies under evaluation :
* Group A: semi-invasive strategy: FOB within 24 hours after ICU admission
* Group B: non-invasive strategy: no FOB within 24 hours after ICU admission
* Evaluation criteria:
Main criteria: Changes in initial empirical antibiotic treatment according to microbiological results obtained in each group.
others
* FOB related complications
* Microbiological results
* Type of antibiotic treatment modifications
* ICU outcome and outcome at day 28
* Duration of antibiotic therapy and nimber of days without antibiotics at day 28 after inclusion
Study:
NCT00308659
Study Brief:
Protocol Section:
NCT00308659